Electrocardiographic Modifications and Spontaneous Hypoglycemic Episodes in Type 1 Diabetes

Sponsor
Institut de Recherches Cliniques de Montreal (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03682250
Collaborator
(none)
29
1
47.4
0.6

Study Details

Study Description

Brief Summary

The population of type 1 diabetes patients with cardiovascular disease is increasing and this study aims to explore the electrocardiographic changes that are associated with spontaneous hypoglycemia in this type of population. More precisely, this study will investigate if these modifications are of the same nature as those already observed in different populations (patients with type 2 diabetes) to see the pro-arrhythmogenic impact of hypoglycemia in patients with type 1 diabetes.

Condition or Disease Intervention/Treatment Phase
  • Device: FreeStyle Libre Pro
  • Device: Holter monitor

Study Design

Study Type:
Observational
Actual Enrollment :
29 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Electrocardiographic Modifications During Spontaneous Hypoglycemic Episodes in Patients With Type 1 Diabetes at High Cardiovascular Risk
Actual Study Start Date :
Sep 17, 2018
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Aug 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Patients with type 1 diabetes with a high cardiovascular risk

Device: FreeStyle Libre Pro
A FreeStyle Libre Pro will be used to identify hypoglycemic episodes

Device: Holter monitor
A Holter monitor will be used to measure heart's activity

Outcome Measures

Primary Outcome Measures

  1. QT intervals corrected for heart rate [48 hours]

Secondary Outcome Measures

  1. Percentage of time between 4.0 and 10.0 mmol/L [48 hours]

  2. Percentage of time below 3.5 mmol/L [48 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Men and women ≥ 18 years old;

  • Be able to give informed consent;

  • Diagnosis of type 1 diabetes for ≥ 6 months;

  • Treated with intensive insulin therapy (multiple injections of insulin or insulin pump)

AND EITHER

  • A history of CV disease defined as: 1) Established diagnosis of atherosclerotic coronary artery disease (example: previous history of infarction); 2) Previous cerebral Vascular Stroke or Transient Ischemic Accident; 3) Anterior revascularization of the coronary arteries, carotid artery or peripheral arteries; 4) At least one coronary stenosis, carotid artery or lower extremity arteries > 50%; 5) History of symptomatic coronary heart disease confirmed with hospitalization or a positive stress test result or by any cardiac imaging result, or unstable angina with changes observed at the ECG; 6) Asymptomatic cardiac ischemia confirmed by a nuclear imaging test, an exercise test, a dobutamine stress echo; 7) NYHA II-III class chronic heart failure;
  1. Amputation of limb or foot due to circulatory insufficiency.
  • Or more than 20 years duration of T1D and at least 2 of the following risk factors or associated condition: 1) Chronic renal failure eGFR <60 ml / min / 1.73 m2); 2) Presence of micro or macro-albuminuria (albumin / creatinine ratio > 2); 3) Hypertension or treatment for hypertension; 4) Hyperlipidemia or treatment for hypolipemia; 5) Abdominal obesity (Waist circumference> 94 cm for men and > 80 cm for women); 6) Smoking ; 7) Significant retinopathy (pre-proliferative, proliferating, laser or intravitreous injection); 8) Body mass index > 30 kg /m2; 9) Erectile dysfunction; 10) Left ventricular hypertrophy; 11) Positive family history of early MCAS (H < 55 years old and F < 65 years old)
Exclusion Criteria:
  • Definitive criteria: 1) QRS > 120 ms on the baseline ECG; 2) Presence of atrial fibrillation at inclusion; 3) Current intake of any drug that may prolong QT according to the judgment of the investigator and the update of the list available on www.professionsante.com.

  • Transient criteria (the patient can be included once the anomaly is corrected): 1) Hypokalemia (< 3.5 mmol/L); 2) Hypocalcemia (ionized calcium < 1.10 mmol/L); 3) Hypomagnesemia (< 0.7 mmol/L)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institut de recherches cliniques de Montréal Montreal Quebec Canada H2W 1R7

Sponsors and Collaborators

  • Institut de Recherches Cliniques de Montreal

Investigators

  • Principal Investigator: Remi Rabasa-Lhoret, Institut de recherches cliniques de Montréal

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rémi Rabasa-Lhoret, Full professor, Institut de Recherches Cliniques de Montreal
ClinicalTrials.gov Identifier:
NCT03682250
Other Study ID Numbers:
  • FRYPOT
First Posted:
Sep 24, 2018
Last Update Posted:
Mar 8, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2022